达比加群酯治疗儿童急性静脉血栓栓塞(DIVERSITY):随机对照开放标签2b/3期非劣效试验
DIVERSITY试验在26国65中心纳入<18岁急性静脉血栓栓塞患儿,按1:2随机接受标准抗凝或年龄体重调整达比加群酯方案。
要点
- 大出血发生率两组相似(2% vs 2%),安全性可接受。
- 年龄体重调整剂量算法适用,药效学关系与成人一致。
核心结论
- 年龄和体重调整的达比加群酯剂量算法适用于0至<18岁静脉血栓栓塞患儿。
- 达比加群酯疗效非劣于标准治疗,药效学关系与成人相似,可能为合适替代。
研究设计与样本
- 随机、对照、开放标签、平行组、2b/3期非劣效试验,26国65中心。
- 纳入<18岁急性静脉血栓栓塞患儿,先接受5-21天肠外抗凝,需抗凝至少3个月。
- 按1:2随机至标准治疗(低分子肝素、普通肝素、维生素K拮抗剂或磺达肝癸钠)或达比加群酯,按年龄分层。
- 共入组328例,267例随机并分析(标准治疗90例,达比加群177例)。
主要发现
- 药效学:达比加群总血浆浓度与稀释凝血酶时间、蛇静脉酶凝血时间呈线性关系,与活化部分凝血活酶时间呈非线性关系,曲线与成人相似。
- 严重不良事件:标准治疗18/90(20%)vs 达比加群22/176(13%);标准治疗组1例治疗中死亡(腹膜后出血,研究者认为与治疗无关)。
关键数值与推荐
- 非劣效界值为绝对差异20%。
临床怎么用
- 达比加群酯可作为儿童静脉血栓栓塞抗凝治疗的替代选择,需按年龄体重调整剂量。
- 治疗期间可监测稀释凝血酶时间或蛇静脉酶凝血时间评估达比加群暴露。
局限性
- 开放标签设计,非双盲。
- 样本量267例,事件数有限。
- 仅纳入初始肠外抗凝后需长期抗凝的患儿,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism. The aims of this clinical trial were to study the appropriateness of a paediatric dabigatran dosing algorithm, and the efficacy and safety of dabigatran dosed according to that algorithm versus standard of care in treating children with venous thromboembolism. METHODS: DIVERSITY is a randomised, controlled, open-label, parallel-group, phase 2b/3 non-inferiority trial done in 65 centres in 26 countries. Standard of care (low-molecular-weight heparins, unfractionated heparin, vitamin K antagonists or fondaparinux) was compared with a paediatric oral dabigatran dosing regimen (an age-adjusted and weight-adjusted nomogram) in children younger than 18 years with acute venous thromboembolism initially treated (5-21 days) with parenteral anticoagulation, requiring anticoagulation therapy for at least 3 months. Patients were randomised 1:2 (standard of care:dabigatran) and stratified by age (12 to <18 years, 2 to <12 years, and birth to <2 years) via interactive response technology. The primary composite efficacy endpoint (intention-to-treat analysis) was the proportion of children with complete thrombus resolution, and freedom from recurrent venous thromboembolism and venous thromboembolism-related death. A non-inferiority margin of absolute differences of 20% was used. Secondary endpoints included safety (determined by major bleeding events [time-to-event analysis on the treated set]), and pharmacokinetic-pharmacodynamic relationships (descriptive analyses). This trial is registered with ClinicalTrials.gov, NCT01895777 and is completed. FINDINGS: 328 children were enrolled between Feb 18, 2014, and Nov 14, 2019. 267 were randomly assigned (90 [34%] to standard of care and 177 [66%] to dabigatran) and included in the analyses. Median exposure to standard of care was 85·0 days (IQR 80·0-90·0) and to dabigatran was 84·5 days (78·0-89·0). Similar proportions of children treated with standard of care and dabigatran met the composite efficacy endpoint (38 [42%] of 90 vs 81 [46%] of 177; Mantel-Haenszel weighted difference, -0·04; 90% CI -0·14 to 0·07; p<0·0001 for non-inferiority). On-treatment bleeding events were reported in 22 (24%) of 90 children receiving standard of care and 38 (22%) of 176 children receiving dabigatran (hazard ratio [HR] 1·15, 95% CI 0·68 to 1·94; p=0·61); major bleeding events were similar between the groups (two [2%] of 90 and four [2%] of 176; HR 0·94, 95% CI 0·17 to 5·16; p=0·95). Pharmacokinetic-pharmacodynamic curves showed a linear relationship between total dabigatran plasma concentration and diluted thrombin time and ecarin clotting time, and a non-linear relationship with activated partial thromboplastin time; curves were similar to those for adults. Serious adverse events were reported for 18 (20%) of 90 children receiving standard of care and 22 (13%) of 176 children receiving dabigatran. The most common severe adverse events were vascular disorders (standard of care three [3%] of 90, dabigatran two [1%] of 176), and gastrointestinal disorders (standard of care two [2%] of 90 and dabigatran five [3%] of 176). One on-treatment death occurred in the standard of care group (retroperitoneal bleeding, not considered treatment related by the study investigators). INTERPRETATION: An age-adjusted and weight-adjusted dabigatran dosing algorithm was appropriate in children aged birth to less than 18 years with venous thromboembolism. Dabigatran was non-inferior to standard of care in terms of efficacy, with similar pharmacokinetic-pharmacodynamic relationships as those seen in adults, and might be a suitable alternative to standard of care. FUNDING: Boehringer Ingelheim.
引用
- Halton J, Brandão LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2020. PMID: 33290737. doi:10.1016/S2352-3026(20)30368-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。